{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:13:50Z","timestamp":1793060030634,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,5]],"date-time":"2023-03-05T00:00:00Z","timestamp":1677974400000},"content-version":"vor","delay-in-days":63,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018836","name":"Sheffield Teaching Hospitals NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.idcr.2023.e01741","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T16:39:18Z","timestamp":1678120758000},"page":"e01741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Ledipasvir\/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection"],"prefix":"10.1016","volume":"32","author":[{"given":"Jennifer","family":"Gallacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusri","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"da Silva Filipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samreen","family":"Ijaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-2453","authenticated-orcid":false,"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.idcr.2023.e01741_bib1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","article-title":"Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on hepatitis E virus infection","volume":"68","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.idcr.2023.e01741_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/TP.0000000000001908","article-title":"Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation","volume":"102","author":"McPherson","year":"2018","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.idcr.2023.e01741_bib3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1215246","article-title":"Ribavirin for chronic hepatitis E virus infection in transplant recipients","volume":"370","author":"Kamar","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.idcr.2023.e01741_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jvh.13424","article-title":"Persistent hepatitis E virus infection across England and Wales 2009-2017: demography, virology and outcomes","volume":"28","author":"Ankcorn","year":"2021","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.idcr.2023.e01741_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2019.04.008","article-title":"Convalescent plasma therapy for persistent hepatitis E virus infection","volume":"71","author":"Ankcorn","year":"2019","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.idcr.2023.e01741_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.gastro.2015.09.011","article-title":"Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin","volume":"150","author":"Dao Thi","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.idcr.2023.e01741_bib7","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jhep.2020.05.020","article-title":"Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - the HepNet SofE pilot study","volume":"73","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.idcr.2023.e01741_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz346","article-title":"Sofosbuvir add-on to ribavirin treatment for chronic hepatitis E virus infection in solid organ transplant recipients does not result in sustained virological response","volume":"6","author":"van Wezel","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.idcr.2023.e01741_bib9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3851\/IMP3227","article-title":"Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective","volume":"23","author":"Todesco","year":"2018","journal-title":"Antivir Ther"},{"issue":"9","key":"10.1016\/j.idcr.2023.e01741_bib10","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1128\/JCM.39.9.3040-3046.2001","article-title":"Evidence of extrahepatic sites of replication of the hepatitis E virus in a swine model","volume":"39","author":"Williams","year":"2001","journal-title":"J Clin Microbiol"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250923000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250923000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:07:54Z","timestamp":1761998874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250923000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":10,"alternative-id":["S2214250923000653"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2023.e01741","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ledipasvir\/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2023.e01741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01741"}}